FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ — Telix Prescribed drugs Restricted (ASX: TLX, NASDAQ: TLX, “Telix”) right this moment broadcasts its monetary outcomes for the yr ended December 31, 2025.

FY 2025 key outcomes¹

Group efficiency²: Double-digit income progress and optimistic adjusted working money movement

• Income of US$803.8 million, up by 56%³ and attaining upsized full yr steerage⁴.
• US$157.1 million invested in analysis and improvement (R&D) product improvement for late-stage therapeutics and precision medication pipeline property⁵, consistent with said FY 2025 steerage.
• Adjusted EBITDA⁶ of US$39.5 million, reflective of elevated working expenditure pushed by strategic acquisitions, funding in industrial infrastructure and analysis and improvement (R&D).
• A non-material loss earlier than tax of US$5.3 million, contains US$26.7 million in non-cash finance prices related to convertible bonds and elevated asset amortization of US$11.9 million (2024: US$5.1 million) following the RLS Radiopharmacies (RLS) acquisition.
• 12 months-end money stability of US$141.9 million following US$246.4 million of strategic investments (M&A) and money generated from working actions of US$34.5 million earlier than the ultimate contingent consideration cost to Superior Nuclear Drugs Components (ANMI) of US$51.8 million⁷.

Telix Precision Drugs: Strengthening industrial profitability, driving progress

• Precision Drugs phase income up by 22% year-over-year, pushed by continued enhance in Illuccix® volumes and profitable launch of Gozellix® within the U.S.
• Gross margin stays secure at 64%.
• Adjusted (phase) EBITDA up by 24% year-over-year to US$216.4 million.
• Promoting and advertising bills of US$82.4 million, reflecting incremental funding in international industrial infrastructure for brand new product launches (Illuccix EU, Gozellix, Zircaix®⁸ and Pixclara®⁸).
• TLX101-Px (Pixclara⁸) regulatory filings: Telix has filed a advertising authorization utility for TLX101-Px in Europe, concurrent to finalizing the New Drug Software (NDA) bundle for the U.S. Meals and Drug Administration (FDA).
• TLX250-Px (Zircaix⁸) submission: Based mostly on the 2 Sort A conferences with the FDA, Telix believes it has aligned on key excellent points for the Biologics License Software (BLA) resubmission, together with demonstration of drug product comparability between scientific trial materials and scale-up industrial manufacturing. The Firm is now finishing the agreed deliverables and documentation required for resubmission.

Telix Manufacturing Options (TMS): Expanded international operations to ship affected person outcomes

• TMS phase contains RLS, IsoTherapeutics (TX, U.S.), and manufacturing (and R&D) amenities in Sacramento (CA, U.S.), Brussels (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a considerably expanded international manufacturing and manufacturing footprint.
• RLS reported US$238.4 million of whole phase income, which incorporates US$170.1 million from third-party product gross sales and repair charges, and US$68.3 million inter-segment income⁹, reflecting wonderful progress in gross sales of Illuccix and Gozellix by way of the RLS community. 
• RLS transitioned to optimistic adjusted EBITDA contribution of US$1.2 million.
• RLS working loss contains US$7.4 million of depreciation and amortization on acquired intangibles.
• Adjusted EBITDA loss for the TMS phase of US$21.7 million, expenditure in step with first half, demonstrating inter-company price management (H1 2025: Adjusted EBITDA lack of US$12.7 million).

Telix Therapeutics: Prioritization of R&D funding in direction of advancing late-stage property

Of the entire R&D funding, US$98.0 million was invested within the therapeutics pipeline. Milestones achieved embody:

• TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan): Accomplished goal enrollment of 30 sufferers for Half 1 of the ProstACT® World¹⁰ Part 3 examine in metastatic castration resistant prostate most cancers (mCRPC). First sufferers handled in Half 2 (randomized enlargement)¹¹.
• TLX250-Tx (¹⁷⁷Lu-DOTA-girentuximab): Obtained regulatory approval to start LUTEON¹², a world Part 2/3 monotherapy trial in metastatic clear cell renal cell carcinoma (ccRCC), initiating websites. First sufferers dosed within the STARLITE-1¹³ Part 1b/2 investigator-initiated trial exploring TLX250-Tx together with cabozantinib and nivolumab in ccRCC.
• TLX101-Tx (iodofalan ¹³¹I): Obtained regulatory approval in Australia and the European Union to start the IPAX-BrIGHT¹⁴ pivotal trial of TLX101-Tx in recurrent glioblastoma (GBM).
• TLX592-Tx (²²⁵Ac-PSMA-RADmAb): Obtained regulatory approval to start AlphaPRO¹⁵, a Part 1, first-in-human (FIH) examine of Telix’s focused alpha remedy (TAT) candidate in superior mCRPC.
• TLX252-Tx (²²⁵Ac-DOTA-girentuximab): Obtained regulatory approval to start ALPHIX¹⁶, a Part 1, FIH examine of Telix’s TAT candidate for the therapy of sufferers with superior metastatic kidney most cancers and different carbonic anhydrase IX (CAIX) expressing cancers.
• TLX300-Px (⁸⁹Zr-olaratumab): First sufferers dosed within the ZOLAR¹⁷ Part 1, FIH imaging examine for sufferers with superior, metastatic smooth tissue sarcoma (STS) and different platelet derived progress issue receptor alpha (PDGFRα) optimistic tumors, aiming to display proof of idea for remedy.
• TLX090-Tx (¹⁵³Sm-DOTMP): First U.S. sufferers dosed in SOLACE¹⁸, a Part 1 examine evaluating security, dosimetry, affected person‑reported outcomes, and potential opioid‑sparing results of TLX090‑Tx in sufferers with metastatic bone ache.

FY 2026 Steering

• Telix gives FY 2026 Group Income steerage of US$950 million to US$970 million. 
• Steering displays income from product gross sales in jurisdictions with a advertising authorization, and a full yr of income contribution from RLS.
• Telix gives pipeline R&D expenditure steerage of US$200 million to US$240 million.

Government Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the end result: “Our robust industrial efficiency in 2025 gives a platform for continued progress throughout Telix’s international Precision Drugs franchise. The income steerage we’re issuing right this moment displays our confidence in sustaining the momentum of our core money generative enterprise. In step with our said technique, we’re reinvesting earnings to prioritize the acceleration of our best-in-class therapeutic pipeline, which now contains three pivotal stage trials in prostate, kidney and mind most cancers. We additionally intend to proceed to broaden the Precision Drugs progress alternative by way of label enlargement research and new product launches. In 2026 we’re targeted on supply of those close to‑time period priorities to additional strengthen the foundations for lengthy‑time period income and earnings progress.”

Abstract: Group monetary outcomes

Investor name

An investor webcast and convention name can be held at 9:30 a.m. AEDT on Friday 20 February 2026 (5:30 p.m. EST Thursday 19 February 2026).
Contributors can register for the webcast or the teleconference by clicking right here: https://edge.media-server.com/mmc/p/famdpwzh

To learn or obtain the 2025 Annual Report and to view the accompanying investor presentation, go to Telix’s Investor Relations web site: ir.telixpharma.com/

About Telix Prescribed drugs Restricted

Telix is a biopharmaceutical firm targeted on the event and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical applied sciences. Telix is headquartered in Melbourne, Australia, with worldwide operations in the US, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is growing a portfolio of scientific and industrial stage merchandise that goals to handle vital unmet medical wants in oncology and uncommon ailments. Telix is listed on the Australian Securities Trade (ASX: TLX) and the Nasdaq World Choose Market (NASDAQ: TLX).

Illuccix® (equipment for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first technology PSMA-PET imaging agent, has been permitted in a number of markets globally. Gozellix® (equipment for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been permitted by the U.S. FDA.

Telix’s osteomyelitis (bone an infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed underneath the model title Scintimun®, is permitted in 32 European international locations and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgical procedure, is registered with the FDA to be used within the U.S. and has attained a Conformité Européenne (CE) Mark to be used within the European Financial Space. No different Telix product has obtained a advertising authorization in any jurisdiction.

Go to www.telixpharma.com for additional details about Telix, together with particulars of the newest share worth, ASX and U.S. Securities and Trade Fee (SEC) filings, investor and analyst displays, information releases, occasion particulars and different publications which may be of curiosity. You may as well comply with Telix on LinkedIn, X and Fb.

Steering Disclaimer

The said income steerage relies on anticipated international and home financial situations and is topic to recognized and unknown dangers, uncertainties and different elements that will trigger our precise outcomes to vary materially. As such, buyers are cautioned to not place undue reliance on this steerage and specifically Telix can’t assure a specific end result. In compiling monetary forecasts, numerous key variables that will have a major affect on steerage have been recognized and are listed under.

Key variables that would trigger precise outcomes to vary materially embody: the success and timing of analysis and improvement actions; selections by regulatory authorities concerning approval of our merchandise in addition to their selections concerning label claims; aggressive developments affecting our merchandise; the power to efficiently market new and present merchandise; difficulties or delays in manufacturing; commerce shopping for patterns and fluctuations in curiosity and forex trade charges; laws or laws that have an effect on product manufacturing, distribution, pricing, reimbursement, entry or tax; acquisitions and divestitures; analysis collaborations; litigation or authorities investigations; and Telix’s means to guard its patents and different mental property.

This announcement has been licensed for launch by the Telix Prescribed drugs Restricted Board of Administrators

Authorized Notices

You must learn this announcement along with our danger elements, as disclosed in our most lately filed reviews with the Australian Securities Trade (ASX), U.S. Securities and Trade Fee (SEC), together with our Annual Report on Type 20-F filed with the SEC, or on our web site.

The knowledge contained on this announcement isn’t supposed to be a proposal for subscription, invitation or advice with respect to securities of Telix Prescribed drugs Restricted (Telix) in any jurisdiction, together with the US. The knowledge and opinions contained on this announcement are topic to alter with out notification.  To the utmost extent permitted by regulation, Telix disclaims any obligation or endeavor to replace or revise any data or opinions contained on this announcement, together with any forward-looking statements (as referred to under), whether or not on account of new data, future developments, a change in expectations or assumptions, or in any other case. No illustration or guarantee, categorical or implied, is made in relation to the accuracy or completeness of the data contained or opinions expressed in the middle of this announcement.

This announcement could comprise forward-looking statements, together with throughout the that means of the U.S. Non-public Securities Litigation Reform Act of 1995, that relate to anticipated future occasions, monetary efficiency, plans, methods or enterprise developments. Ahead-looking statements can typically be recognized by means of phrases resembling “could”, “anticipate”, “intend”, “plan”, “estimate”, “anticipate”, “consider”, “outlook”, “forecast” and “steerage”, or the damaging of those phrases or different comparable phrases or expressions. Ahead-looking statements contain recognized and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. Ahead-looking statements are primarily based on Telix’s good-faith assumptions as to the monetary, market, regulatory and different dangers and concerns that exist and have an effect on Telix’s enterprise and operations sooner or later and there may be no assurance that any of the assumptions will show to be right. Within the context of Telix’s enterprise, forward-looking statements could embody, however will not be restricted to, statements about: the initiation, timing, progress, completion and outcomes of Telix’s preclinical and scientific trials, and Telix’s analysis and improvement packages; Telix’s means to advance product candidates into, enroll and efficiently full, scientific research, together with multi-national scientific trials; the timing or chance of regulatory filings and approvals for Telix’s product candidates, together with the deliberate NDA resubmission for TLX101-Px and the deliberate BLA resubmission for TLX250-Px, manufacturing actions and product advertising actions; Telix’s gross sales, advertising and distribution and manufacturing capabilities and techniques; the commercialization of Telix’s product candidates, if or after they have been permitted; Telix’s means to acquire an ample provide of uncooked supplies at cheap prices for its industrial merchandise and product candidates; estimates of Telix’s bills, future revenues and capital necessities; Telix’s monetary efficiency; developments referring to Telix’s opponents and trade; the anticipated affect of U.S. and overseas tariffs and different macroeconomic situations on Telix’s enterprise; and the pricing and reimbursement of Telix’s product candidates, if and after they’ve been permitted. Telix’s precise outcomes, efficiency or achievements could also be materially totally different from these which can be expressed or implied by such statements, and the variations could also be hostile. Accordingly, you shouldn’t place undue reliance on these forward-looking statements.

Non-IFRS Monetary Measures. Telix’s outcomes are reported underneath Worldwide Monetary Reporting Requirements (IFRS). This announcement contains varied non-IFRS monetary data to mirror its underlying efficiency, which haven’t been topic to audit or assessment. These non-IFRS measures embody Adjusted EBITDA, which represents internet earnings attributable to the Group excluding internet finance prices, earnings tax expense, depreciation and amortization and different positive factors/(losses) (internet). As required by SEC guidelines, we now have offered reconciliations of those non-IFRS monetary measures to probably the most instantly comparable IFRS measures, which for Adjusted EBITDA, is Revenue/(loss) earlier than earnings tax. The Group believes that these non-IFRS measures, which aren’t thought of to be an alternative choice to or superior to IFRS measures, present stakeholders with extra helpful data on the underlying developments, efficiency and place of the Group and are in step with how enterprise efficiency is measured internally. The non-IFRS measures will not be outlined by IFRS and subsequently might not be instantly comparable with different corporations’ different efficiency measures.

Emblems and Commerce Names. All emblems and commerce names referenced on this press launch are the property of Telix Prescribed drugs Restricted (Telix) or, the place relevant, the property of their respective homeowners. For comfort, emblems and commerce names could seem with out the ® or ™ symbols. Such omissions will not be supposed to point any waiver of rights by Telix or the respective homeowners. Trademark registration standing could range from nation to nation. Telix doesn’t intend the use or show of any third-party emblems or commerce names to suggest any affiliation with, endorsement by, or sponsorship from these third events.

©2026 Telix Prescribed drugs Restricted. All rights reserved.